Total period Within 5 years   OR (95%CI) p OR (95%CI) p Male 0.866 (0.501-1.498) 0.607   1.322 (0.422-4.144) 0.630 Age (≧50y.o.) 1.226 (0.634-2.372) 0.544 7.011 (2.560-19.196) <0.001 Age (≦20y.o.) 0.484 (0.172-1.365) 0.161 0.492 (0.064-3.774) 0.486 HD (≧10years ) 1.275 (0.526-3.091) 0.590 1.716 (0.380-7.737) 0.476 Preemptive 0.751 (0.315-1.795) 0.518 2.494 (0.787-7.901) 0.108 Deceased donor 0.599 (0.211-1.697) 0.329 1.276 (0.284-5.722) 0.740 Diabetic Nephropathy 1.266 (0.436-3.678) 0.664 6.657 (2.045-21.667) <0.001 AR(+) 0.813 (0.451-1.466) 0.490 0.554 (0.156-1.963) 0.353 ABO-i 1.024 (0.394-2.657) 0.961 5.785 (1.940-17.244) <0.001 Immunosuppression         Tac 0.701 (0.338-1.455) 0.337 2.659 (0.950-7.438) 0.053 CsA 0.494 (0.293-0.831) 0.007 0.692 (0.257-1.865) 0.465 MMF 0.606 (0.282 -1.302) 0.195 4.510 (1.663-12.225) 0.001 Bas 0.092 (0.022-0.380) <0.001 0.437 (0.098-1.940) 0.263 Rit 0.365 (0.049-2.719) 0.304 1.611 (0.206-12.602) 0.646 Conventional 2.912 (1.712-4.954) <0.001 0.491 (0.110-2.184) 0.340

OR: Odds Ratio, CI: Confidence Interval, HD: Hemodialysis, AR: Acute Rejection, ABO-i: ABO-incompatible, Tac: Tacrolimus, CsA: Cyclosporine, MMF: Mycophenolate Mofetil, Bas: Basiliximab, Rit: Rituximab. *Conventional: CNI was not applied, but only antimetabolite and steroid was used

Table 2: Risk factor for post-transplant malignancy assessed by univariate analysis.